China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd, (HKG: 2315) has announced an antibody assessment and option agreement with US firm Neurocrine Biosciences Inc. The agreement grants Neurocrine access to Biocytogen’s fully human antibodies targeting multiple specified therapeutic areas, with an option to license selected antibodies for global development, manufacturing, and commercialization. The collaboration may be expanded to include additional targets upon mutual consent. The antibodies in question were developed using Biocytogen’s proprietary RenMice platforms.
According to the agreement, should Neurocrine choose to exercise the options, Biocytogen stands to receive option-exercise fees, development and commercialization milestone payments, and single-digit royalties on net sales for each selected target.-Fineline Info & Tech
